BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

1

Autologous hematopoietic stem cell transplantation (HSCT) is an effective treatment for resistant inflammatory types of multiple sclerosis (MS).
2

The EBMT registry has reported over 2000 MS patients treated with HSCT since 1995, showing a trend towards earlier intervention in relapsing-remitting MS.
3

BEAM/ATG and cyclophosphamide/ATG are the two main conditioning regimens used in HSCT for MS, both included in EBMT guidelines.
4

A retrospective study indicated NEDA rates at 5 years were 81% for BEAM/ATG and 71% for CYC/ATG, with more severe adverse events linked to BEAM/ATG.
5

This observational study aims to compare the safety and efficacy of BEAM/ATG and CYC/ATG regimens using data from the EBMT registry.

Bone Marrow Transplantation

by Raffaella Greco, Riccardo Saccardi, Marta Ponzano, Manuela Badoglio, Grzegorz Helbig, Marek Smilowski, Alice Mariottini, Joachim Burman, Kristina Carlson, Majid Kazmi, Paolo A. Muraro, Ian Gabriel, Barbara Withers, Jennifer Massey, Riccardo Varaldo, Matilde Inglese, Jaime Sanz, Sara Gil-Perotin, Basil Sharrack, Elisa Roldan, Chiara Nozzoli, Alessio Signori, Maria Pia Sormani, Tobias Alexander, John A. Snowden
September 29, 2025

1